id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1999-P-0126-0007,FDA,FDA-1999-P-0126,FDA/CDER to GlaxoSmithKline,Other,PAV-Petition Approval,2002-07-12T04:00:00Z,2002,7,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9f3
FDA-1999-P-0126-0008,FDA,FDA-1999-P-0126,FDA/CDER to Pharmacia & Upjohn,Other,PAV-Petition Approval,2002-07-12T04:00:00Z,2002,7,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9f5
FDA-1999-P-0126-0006,FDA,FDA-1999-P-0126,FDA/CDER to Pharmacia & Upjohn,Other,LET-Letter,2000-04-06T04:00:00Z,2000,4,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9f2
FDA-1999-P-0126-0004,FDA,FDA-1999-P-0126,FDA/DMB to Pharmacia & Upjohn Inc.,Other,CR-Correction,1999-10-26T04:00:00Z,1999,10,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9ee
FDA-1999-P-0126-0003,FDA,FDA-1999-P-0126,FDA/DMB to Pharmacia & Upjohn,Other,ACK-Acknowledgement Letter,1999-10-26T04:00:00Z,1999,10,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9ed
FDA-1999-P-0126-0002,FDA,FDA-1999-P-0126,FDA/CDER to Glaxo Wellcome Inc,Other,LET-Letter,1999-09-14T04:00:00Z,1999,9,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9eb
FDA-1999-P-0126-0001,FDA,FDA-1999-P-0126,FDA/DMB to Glaxo Wellcome Incorporated,Other,ACK-Acknowledgement Letter,1999-03-04T05:00:00Z,1999,3,,,2008-04-25T00:19:51Z,,0,0,09000064804ae9e6